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I. General Introduction

A.

Chronic Kidney Disease: Overview and Current Concepts

Chronic kidney disease (CKD) is a generalized term for a variety of chronic
conditions that result in compromised kidney functions[l]. Under normal
physiologic conditions, the kidneys serve several functions: regulation of fluid
volume and the acidlbase balance of plasma; excretion of nitrogenous waste;
synthesis of erythropoietin, 1,25-dihydroxy-cholecalciferol, and renin; and
different drug metabolism[2]. Kidney function is assessed by the glomerular
filtration rate (GFR), which is estimated by the use of the following formula[3]:

GFR (mumin per 1.73 m2) = 186 x (S~,)-'.'~~X
( ~ ~ e x) (0.742
- ~ . if~female)
~ ~
x (1.210 if African-American),

where Sc, is serum creatinine concentration in mgIdL, and age is in years.
Based on the estimated GFR, there are five stages of CKD[3] as presented in
Table 1. CKD stage 5, known as End-Stage Renal Disease (ESRD), is defined
by GFR <15 mllminll .73m2and characterized by bilateral, progressive, chronic
deterioration of nephrons, which are the kidney functional units. The kidneys are
no longer able to maintain normal homeostasis resulting in uremia caused by
renal failure, retention of excretory products, and interference with endocrine and
metabolic functions[4]. Stages 3 and 4 can also be characterized by uremia, but
usually in lower levels than stage 5[5]. Stage 5 is caused by any condition that

could potentially destroy the nephrons, but the most common causes are
diabetes mellitus, hypertension, and glomerulonephritis[6].

When the patient is diagnosed with CKD stage 5, the goals of treatment are to
maintain quality of life, control disease progression and prevent further
complications. At this stage, treatment focuses on dietary modification in an
effort to decrease the retention of nitrogeneous waste products and control fluid
and electrolyte imbalances[7]. When conservative treatment fails and the
number of functional nephrons is reduced to the point that the kidneys can no
longer filter the blood and adequately remove nitrogen-containing compounds,
either renal replacement therapy or renal transplantation is necessary[8].

Renal replacement therapy (dialysis) is a medical procedure that facilitates the
removal of water and waste products such as creatinine and urea from the blood.
More than 350,000 individuals receive dialysis in the United States at a cost of
more than $7 billion per year[9]. The procedure can be accomplished by ei,ther
peritoneal dialysis or hemodialysis. Peritoneal dialysis involves infusion of a
hypertonic solution into the peritoneal cavity 4 to 5 times per day via a
permanently placed peritoneal catheter[lO].

The most common type of renal replacement therapy is hemodialysis therapy

(HD), with approximately 90% of dialysis patients receiving this form of
treatment[9]. HD treatments are performed every two or three days, usually

three or four hours each through vascular access connected to the hemodialysis
device. Vascular access is accomplished by a permanent and surgically-placed
arteriovenous (AV) fistula, a graft or a venous catheter. From 1996 to 2007, AV
fistula use rose from 24% to 47% among HD patients in the US[1 I ] . Despite
being a life-saving technique, HD only provides about 15% nephron function[l2]
and the I-year survival rate is 78%, while the 5-year survival rate is 28%[13].
The procedure requires a substantial time commitment from the patient and
potential complications include potential infection of the fistulalgraft site,
septicemia, infective endocarditis, cardiovascular disease, hypotension[l4],
hypoxemia, and arrythmias[l5]. Renal transplantation is a long-term alternative
to dialysis, but in itself is also associated with a significant number of
complications such as cardiovascular complications[l6] and increased
susceptibility to infection or malignancies[l7] despite offering obvious
advantages such as elimination of dialysis time commitment, fewer diet and fluid
restrictions, and a better quality of life[l2].

CKD is a major global health issue. It is estimated that up to 19 million
Americans have CKD and 350,000 are currer~tlyon dialysis[l8]. Each year,
approximately 79,000 new cases of stage 5 CKD are diagnosed-a

rate of 1.3 in

10,000 persons. Approximately 60,000 Americans die annually as a result of
stage 5 with cardiovascular disease being the main cause of mortality in this
population[l9].

6.

Inflammation: Role in Chronic Kidney Disease and

Outcomes

lnflammation is the biological response of tissue to harmful stimuli such as
pathogens or irritants[20]. Research has shown inflammation to be a common
feature in patients suffering from CKD. 30-50% of dialysis patients showed
evidence of an elevated inflammatory response as indicated by high levels of
serum C-reactive protein (CRP) [21]. Other studies have found similar results in
regards to CRP levels in ESRD patients[22-241,

Identifying the sources of inflammation in CKD patients is still under invedigation
Evidence supports the idea that deterioration of renal function is associated with
increased serum cytokine levels[25], while other studies showed that increased
levels of advanced glycation end products due to decreased renal clearance are
contributory factors to vascular inflammation [26]. Persistent infections such as
Chlamydia pneumoniae[27, 281, clotted access grafts[29], and dental
infections[30, 311 have also been suggested as possible sources of inflammatory
responses in CKD patients.

Over the past decade, inflammation has been found to play a strong role in the
pathogenesis of atherosclerosis in patients with ESRD[32] and associations
between inflammation and endothelial dysfunction have been documented[21].
Inflammatory markers such as high sensitivity C-reactive protein (hsCRP) and

the pro-inflammatory cytokine interleukin-6 (IL-6) are elevated in ESRD patients
with cardiovascular disease (CVD)[33]. CRP is a powerful risk predictor for the
development of CVD[34-361, and this inflammatory burden has been suggested
to be a significant contributor to the high CVD-induced mortality rate in dialysis
patients[37].

In addition, inflammatory markers including serum CRP and IL-6 have been
documented as strong predictors of HD poor outcome. Elevated CRP levels
have been associated with increased mortality in both hemodialysis[35, 38, 391
and peritoneal dialysis patients[40], as well as otherwise healthy adults[41].
Elevated serum IL-6 levels have also been shown to predict myocardial infarction
in non-renal patients, as well as mortality in the elderly[42, 431.

C.

Periodontitis: Association with Systemic Inflammation

Periodontal diseases are chronic, predominantly Gram-negative infections of the
oral cavity that are initiated in ,the gingiva and, if untreated, lead to alveolar bone
destruction and eventual tooth loss[44, 451. Collectively, periodontal diseases
affect over 70 percent of the adult population[46].

During the past two decades, a field of periodontal research known as
"periodontal medicine" has emerged[47], investigating the link between
periodontal disease and other systemic diseases. Recent evidence suggests
6

that there may be an association between periodontal infections and several
systemic conditions including diabetes[48, 491, pneumonia[50], cardiovascular
disease[51-54], and adverse pregnancy outcomes[55, 561, although other
investigators have found conflicting results[57, 581.

For more than a century, clinical researchers have been investigating the biologic
mechanism that could explain the link between periodontal infections and
systemic inflammatory diseases. In 1900, Hunter proposed the "Focal lnfection
Theoryn[59],which supports the role of bacterial by-products from a chronic,
localized infection that could be disseminated throughout the body and cause
disease in other organs[60]. This idea led to preventative full-mouth extractions
in patients assessed susceptible to any diseases. This practice was based on
anecdotal evidence. Full mouth tooth extraction often failed to prevent systernic
diseases[61] confirming that the hypothesis was not valid. As a result, the Focal
lnfection Theory collapsed by the 1950s[62]. Recently, periodontal research has
focused on systemic conditions such as diabetes mellitus, cardiovascular
disease, and CKD that have been shown to have an inflammation-linked
pathogenesis [33, 63, 641. The underlying hypothesis is that periodontitis may
contribute to overall systemic inflammation and affect the existing systemic
disease status. Evidence has shown elevated serum levels of CRP as well as
inflammatory cytokines such as IL-6 in patients with periodontal disease [65-671.
The idea that periodontal infections can contribute to systemic inflammation is
further validated by evidence indicating that treatment of periodontal disease can

reduce systemic levels of CRP, IL-6[68-701, and improve endo,thelialfunction[63,

70-721.

Based on the above, the underlying hypothesis of this research project was
developed as shown below: CKD subjects compared to healthy controls have
higher prevalence of periodontal infections that alter systemic inflammatory
status leading to poor renal outcome.

II. Periodontitis in CKD Patients
A.

Obiectives

Hypothesis:

1.

CKD subjects have higher prevalence of severe periodontitis than
healthy controls.

Specific Objectives:

2.

Using a population of stable CKD patients and healthy controls, we
aimed to:

a>

Assess the prevalence of severe periodontitis in HD
and pre-dialysis patients and compare to healthy
controls.
Assess the relationship between periodontal status and
renal function.

Introduction:

Evidence on the prevalence of periodontitis in the CKD population is conflicting.
In a cross-sectional study of 45 dialysis patients, Naugle and co-workers[73]
found that 100% of subjects displayed some form of periodontal disease,
although the majority of patients (64%) had mild periodontitis or gingivitis.
Conversely, Marakoglu et a1[74] found no difference in clinical parameters of
periodontal disease between 36 chronic renal failure patients on hemodialysis
and 36 age and gender matched systemically healthy controls. The authors
concluded that chronic renal failure did not seem to be a risk factor for more
severe periodontal destruction. More recent studies have reported more severe
periodontal destruction in renal failure patients compared to the general
population[75]. In addition, CKD subjects are characterized by some wellestablished risk factors of periodontitis such as poor oral hygiene[76] and
diabetes[77]. Because of the conflicting available evidence, it was the goal of
this study to further explore the prevalence of periodontitis and its role on
systemic inflammation in CKD patients.

C.

Materials & Methods:

1. Subject recruitment
Based on studies by Borawski et a1.1751 and Chen et a1.1761, our power analysis
estimated that 27 HD, 27 pre-dialysis CKD and 58 systemically healthy control
patients would need to be recruited in order to identify a difference in
periodontitis prevalence between HD, CKD and systemically healthy. However,
since this was a one-year pilot feasibility study, we limited our sample size.

Twenty-one CKD patients, including twelve hemodialysis (HD) and nine stage 34 (pre-dialysis) CKD patients were recruited from the University of Connecticut

Health Center (UCHC) Dialysis Unit and Nephrology Clinic after consultation with
their nephrologist. In addition, thirteen non-CKD patients were recruited from
UCHC personnel and served as healthy controls. Smokers were excluded from
the study. The inclusion criteria were as follows: 1) a minimum of 15 teeth 2) no
use of antibiotics within the past month 3) no periodontal treatment within the
past year 4) absence of systemic infection 5) for the HD patients, no history of
vascular access infection within the past month. The study was approved by the
UCHC Institutional Review Board (IRB). All patients signed a consent form to
enter the study.

2. Data Collection
Medical Data
Medical information of the CKD patients was extracted from hospital records
using a standardized extraction form (see Appendix) that included age, gender,

ethnicity, weight, height, diabetes status, history of cardiovascular disease and
hypertension, primary diagnosis, medication history including use of antihyperlipidemic or non-steroidal anti-inflarr~matoryagents. Additionally, the most
recent biochemical data were extracted from the charts including serum albumin,
blood urea nitrogen (BUN), creatinine, ferritin level, total iron binding capacity
(TIBC), total cholesterol, high density lipoprotein (HDL) cholesterol, low density
lipoprotein (LDL) cholesterol, and triglycerides. For HD patients, dialysis vintage
was recorded. A detailed medical history questionnaire (see Appendix) was used
in the control group.

Parameters of Periodontal Status
All patients received a full-mouth periodontal examination, which included clinical
attachment loss (CAL), probing depth (PD), bleeding on probing (BOP), and
plaque score (PS)[78] at six sites on all teeth. Based in part on work from
Arrnitage[79] and Offenbacher[80], severe chronic periodontitis was defined as a
minimum of 2 sites with pocket probing depth (PPD) r5mm, associated with
r5mm CAL with 230% of sites exhibiting BOP. A subject was considered
periodontally healthy if all of the following criteria were met: 1) full-mouth BOP
~30%
of sites, 2) fewer than 2 sites with PPD >4mm and 3) fewer than 2 teeth
per quadrant with evidence of CAL r5mm.

3. Statistical analysis
All continuous variables were tested for normality. When a continuous variable
was not normally distributed it was treated with logarithmic transforma,tionto
achieve normality. Data were analyzed using Student's t test, ANOVA, and posthoc Bonferroni testing. A p value of s0.05 was considered statistically significant.
A computer software program' was used for the statistical analyses.

D.

Results:

1. Population characteristics
Population demographics of the test and control groups are presented in Table 2.
The control group had more female and younger participants compared to the
test group, although these differences did not reach statistical significance. The
test group contained significantly more diabetics than the control group (35.0
percent versus 7.6 percent, p=0.0001).

2. General periodontal findings
Periodontal findings between CKD and control subjects are listed in Table 3 and
Figures 1-3. Severe periodontitis was found in 47.4 percent of CKD subjects,
compared to 15.4 percent of controls (p=0.02). Control subjects had significantly

-

-

-

SPSS 16,SPSS Inc.

fewer missing teeth than CKD subjects (mean 4.62k0.56 versus 8.0923.23,
p=0.01). Compared to healthy controls, CKD subjects had significantly higher
mean PD (2.66k0.09mm versus 2.420.1Omm, p=0.03) and CAL (3.21k0.18mm
versus 2.4720.10mrn1p=0.004) (Figure 2). As shown in Figure 3, CKD subjects
had significantly more sites with CAL;rSmrn (mean 16.80k4.22 percent versus
2.5551.5 percent, p=0.001). There were no significant differences in mean PS
and BOP between CKD and control groups, although both parameters tended to
be higher in the CKD group.

3. Periodontal findings and dialysis status
The periodontal data of the study population stratified into three groups based on
CKD stage (CKD 3-4lPre-diaysis, CKD 5/HD, Healthy) are shown in Table 4 and
Figures 4-6. Although severe periodontitis was more prevalent in the
hemodialysis and pre-dialysis groups compared to controls, the difference did not
reach statistical significance. 'There were significant differences in PD (p=0.049),
CAL (p=0.002), CAL15mm (p=0.016), and missing teeth (p=0.030) among the
groups. Pre-dialysis patients had significantly more missing teeth than healthy
controls. HD subjects had significantly higher mean PD (2.8020.IIrrlm versus
2.420.1Omm, p<0.05), CAL (3.3220. 19mm versus 2.47k0.1Omm, p<0.05), and
CAL25mm (22.01k6.49 percent versus 2.55kI .5 percent, p<0.05) compared to
control subjects. Pre-dialysis subjects also had higher PD and CAL compared to
controls, but 'this difference only reached significance for CAL (3.06+_0.244mm

versus 2.47*0.10mm, ~ ~ 0 . 0 5There
).
was no statistical difference in mean BOP
or PS among the three groups (p>0.05).

E.

Discussion

In our study, severe periodontitis was prevalent in 47.4 percent of CKD patients,
compared to 15.4 percent of controls. This difference was statistically significant.
Additionally, when comparing continuous periodontal parameters, mean PD and
CAL emerged as statistically significant. The difference in the mean values of
continuous periodontal parameters (CAL, PD) between CKD and healthy groups
was explained by the significantly higher percentage of diabetics in the CKD
group as compared to the control group that has been shown to positively affect
severity of periodontitis[81]. A possible solution to controlling this variable could
be to exclude diabetics in our study population, although this would limit the
number of CKD subjects as diabetes is the leading cause of renal failure,
accounting for 44 percent of new cases in 2005[82]. Chuang and co-workers[83]
compared 43 diabetic with 85 non-diabetic ESRD patients on HD. Decreased
salivary flow and pH was associated with increased caries rates in the diabetic
group but no difference was reported for gingival inflammation or periodontitis.

While the CKD group had a higher prevalence of periodontitis, BOP was similar
among the groups. This is likely due to the similar plaque scores between CKD
and control patients, as presence of plaque has been associated with gingival
inflammation, and mechanical removal of plaque is followed by clinical changes
associated with healthy gingiva[84]. In spite of similar plaque scores, CKD
patients had more periodontal destruction than healthy controls. This can be
explained by the significantly higher percentage of diabetics in the CKD group, as
diabetes is an established risk factor for gingivitis and periodontitis[48, 851. It is
unknown whether the dental plaque of CKD patients differs in composition from
that of healthy controls, but studies corr~parirlgplaque pH of children with chronic
renal failure compared to renal transplant or healthy children have shown the
plaque from children with ESRD to be significantly more alkaline. It has been
postulated that this difference in plaque pH may account for the low prevalence
of caries in the CKD population[86], but it is unknown if this affects periodontal
status. Also, CKD patients on HD are characterized by uremia, which has been
associated with defects in lymphocyte and monocyte function[87]. Lymphocytes
and monocytes play important roles in immune response, and defects in the
function of these cells have been associated with aggressive forms of periodontal
disease[88] and therefore may play a role in the increased amount of periodontal
destruction seen in these patients.

The data on the prevalence of periodontitis in CKD populations are conflicting.
Direct comparison of results to other studies is difficult owing to the different

definitions of periodontitis used by different research groups. The periodontitis
definition in this project was selected based on the current classification system
used by the American Academy of Periodontology[79] that defines severe
periodontitis as the presence of a single site with CAL 25mm. BOP was added to
this definition because a recent classification system [80] that identified new
clinical and distinct biologic phenotypes at the biofilm-gingival interface (BGI)
based upon DNA checkerboard analyses of plaque bacteria, serum
immunoglobulin G (IgG) titers to bacteria, and gingival crevicular fluid (GCF)
levels of inflammatory mediators includes BOP as one defining parameter. For
example, a BGI-deep lesionlmoderate bleeding was defined as one or more sites
with PD 24mm and BOP extent scores between 10 and 50 percent.

The prevalence of severe periodontitis did not differ significantly among control,
hemodialyis, and pre-dialysis groups. Compared to HD patients, there were no
significant differences with pre-dialysis subjects in regard to any of the
periodontal parameters measured. Pre-dialysis patients had significantly higher
mean CAL compared to controls. These results are different than those from
Borawski[75], who found significantly higher mean CAL among hemodialysis
patients compared to pre-dialysis patients. A direct corr~parisonof prevalence of
periodontitis to our results could not be performed owing to differences in the
definition of periodontal disease, but pre-dialysis patients in Borawski's study had
significantly higher community periodontal index and treatment needs (CPITN)
scores than those patients on hemodialysis or controls, indicating an increased

prevalence and severity of periodontal disease in this population. The
differences in sample size conipared with our pilot study could also account for
the conflicting results. Further large-scale studies with a standardized approach
to evaluating the periodontal status of pre-dialysis populations are needed.

The cross-sectional design of this study prevents us from determining any causeeffect relationships between periodontal disease and chronic kidney disease. It
is possible that this association may be due to a direct cellular effect on the
nephron unit or its vasculature by periodontal pathogens. While a direct cellular
invasion of periodontal pathogens in renal tissue has yet to be shown,
periodontal pathogens have been shown to invade coronary and aortic
endothelial cells[89, 901. Furthermore, periodontitis patients have been shown to
have chronic and recurrent episodes of low-level bacteremia[91, 921. Some have
hypothesized that bacteria may be filtered out of the blood at the glomerulus,
where these organisms or their products may invade capillary endothelium or
mesangial cells/matrix[93]. Future studies are needed to confirm the role of
periodontal pathogens on renal tissue.

II1.Serum Inflammatory Markers in CKD Patients

Objectives:

1. Hypothesis:
Inflammatory periodontal disease in CKD patients contributes to
systemic inflammatory response, which may affect clinical
outcomes.

2. Specific Objectives:
Using a population of stable CKD patients and healthy controls, we
aimed to:
a>

Assess the levels of the systemic inflammatory markers,

IL-6 and CRP, in the presence or absence of periodontal infection
in HD and pre-dialysis CKD populations compared to healthy
controls.

Introduction:

The role of inflammation in the pathogenesis of periodontal disease and other
systemic diseases has been documented[94-961. Although the exact pathogenic
mechanism remains unclear, one hypothesis is that elevated amounts of
inflammatory cytokines are released locally from the diseased periodonti~~m
into
the bloodstream, leading to an increase in serum cytokines at the systemic level,
thus contributing to disease outcomes. Diseased periodontal tissues have been
shown to possess higher levels of IL-6 than healthy tissues[97, 981, and serum
CRP has been shown to be elevated in patients suffering from periodontitis[99].
Additionally, evidence has shown that treatment of periodontal disease may be
associated with reduced serum levels of inflammatory markers and
corresponding irr~provementin glycemic contro1[100] and endothelial function[63],
although the evidence is conflicting.

The leading cause of mortality in CKD patients is cardiovascular disease,
regardless of CKD stage [ I 01, 1021 [ I 031. Elevated levels of inflammatory
markers such as CRP and IL-6 are known predictors of cardiovascular outcomes
in the HD population[l04], and are linked to hypoalbuminemia, malnutrition,
ery'thropoietin resistance and increased mortality[l05, 1061.

It has been recognized that approximately 30-50% of CKD[107] [I081 patients
have evidence of a systemic inflammatory response which may be caused by

persistent infections[27]. Since periodontitis as a chronic persisting infection has
been associated with systerr~icelevation of inflammatory markers [99], it may
also predict poor outcomes in CKD populations. Therefore, we hypothesize that
severe periodontitis may represent a "non-traditional" risk factor for elevated
systemic inflammation in CKD populations.

Materials & Methods:

1. Subject recruitment
Based on studies by Borawski et a1.[75] and Rao et a1.[104], our power analysis
estimated it would be necessary to recruit 43 HD, 43 pre-dialysis, and 15 healthy
controls for CRP assessment and 29 HD, pre-dialysis, and healthy controls for
IL-6 assessment. For the purposes of this analysis in this pilot feasibility study,
the same group of subjects described in Objective 1 was used. The subjects
signed a consent form that was approved by the Institutional Review Board (IRB)
as described before. Medical and biochemical data were retrieved from the
medical records as described in Objective 1.

2. Blood sampling and analysis
In HD subjects, blood samples were drawn from the arterial end of the vascular
access immediately before initiation of the HD and then stored at -70' until

assay. In pre-dialysis and control subjects, 15 ml venous blood was collected
prior to the oral clinical examination by a certified phlebotomist.

Within 2 hours of blood collection, sera were separated after clotting for 30
minutes at 4OC, followed by centrifugation at 3,000 x g for 15 minutes. Aliquots
were stored at -80°C until testing. Sera were coded and analyzed in duplicate by

€LISA' without the knowledge of the periodontal disease or CKD status of the
study participants. The IL-6 and CRP assay analytical sensitivities were 2.0 pglml
and <0.3 mgIL, respectively, and the variation in protein values within runs was
< I % for both assays.

3. Statistical analysis
Continuous variables were tested for normality and logarithmically transformed if
skewed. IL-6 and CRP levels were compared among the groups by Student's t
test, ANOVA, and post-hoc Bonferroni test. Pearson's correlation coefficients
were calculated to test the associations between serum CRP, serum IL-6, and
periodontal variables. Any variables that had an association with rr0.5 were
included at the multivariate regression analysis as confounders. A multivariate
linear regression model was run, using serum CRP and IL-6 as dependent
variables and testing periodontitis as a predictor variable and adjusting for
confounders based on the significance of the correlation coefficient. A p value of
50.05 was considered statistically significant.
1
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I. Serum inflammatory markers and CKD status
Serum CRP and IL-6 levels for control and CKD patients are listed in Table 5 and
shown in Figures 7 and 8. CKD patients had a higher mean CRP levels (median
3.87, range 0.30-78.35pglml) compared to controls (median 1.41, range 0.4218.00pglml). This difference was statistically significant (p=0.014). Similarly, IL6 levels were higher in CKD patients (median 8.72, range 0.60-9.92pglml) when

compared to control subjects (median 4.00, range 2.00-5.82pglml). This
difference was also statistically significant (p=0.038).

Table 6 and Figures 9 and 10 show CRP and IL-6 levels in subjects according to
renal status (hemodialysis, pre-dialysis, and controls). There were significant
differences between the groups for both CRP and IL-6. In regard to serum CRP
levels, control subjects (median 1.41, range 0.42-18.00pglml) had lower values
than hemodialysis (median 5.78, range 1.87-41.80pglml) and pre-dialysis
(median 2.48, range 0.30-78.35pglml) patients. This difference reached
).
were no significant
statistical significance for HD palients only ( ~ ~ 0 . 0 5There
differences between hemodialysis and pre-dialysis groups (p>0.05). Serum IL-6
levels were significantly elevated in hemodialysis patients (median 10.98, range
6.01-29.35pglml) compared to pre-dialysis patients (median 4.00, range 0.609.92pg/mll p ~ 0 . 0 5and
) control subjects (median 4.00, range 2.00-5.92pgIm1,
pc0.05). There were no significant differences between pre-dialysis and control
subjects (p>0.05).

2.

Serum inflammatory markers and periodontal status

Table 7 and Figures 11 -12 show CRP and IL-6 levels in subjects stratified based
on the periodontal status. Subjects with severe periodontitis had lower serum
CRP levels (median 2.935, range 0.21-41.8~glml)than periodontally-healthy
subjects (median 3.26, range 0.42-78.32pg/ml), but this difference was not
significant (p>0.05). In contrast, IL-6 levels in subjects with severe periodontitis
(median 6.175, range 2.00-29.35pglml) were significantly higher compared to
subjects without periodontitis (median 4.63, range 2.00-1 1.35, p=<0.05).

3.

Association between inflammatory markers and periodontal

parameters
Correlations between serum IL-61CRP levels and periodontal parameters are
presented in Table 8. Both serum IL-6 and CRP levels were significantly related
to PS (r=0.385; p=0.039 and r=0.372; p=0.047, respectively). There was a trend
toward significance for the associations between serum IL-6 levels and CAL
(r=0.281, p=0.140). In contrast to IL-6, serum CRP levels were highly related to
CAL (r=0.500, p=0.006) as well as CAL25mm (r=0.409, p=0.027). There was
also a trend toward significance for the relationships between serum CRP levels
and BOP (r=0.294, p=0.122) and PD (r=0.307, p=0.106). Furthermore, there
was a significant correlation between periodontal status and serum IL-6 (r=0.441,
p=0.045) as well as CRP and IL-6 (r=0.450, p=0.041) among CKD patients.

Multivariable linear regression analysis models were constructed to assess the
interaction between medical and periodontal parameters and serum IL-6 and
CRP levels in the CKD patients. Usirrg serum IL-6 as a dependent variable
(Table 9), HD status was a significant predictor for elevated serum IL-6 levels
(p=0.029), but periodontal status was not (p=0.350). The interaction between HD
and periodontal status was also not significant (p=O.161). When serum CRP was
used as the dependent variable (Table lo), there was a significant effect of
gender (p=0.028) and BMI (p=0.013), and dialysis status was a significant
predictor of elevated serum CRP (p=0.012), but periodontal status was not
(p=0.432). The interaction between HD and periodontal status did not have a
significant effect on serum CRP levels (p=0.256).

E.

Discussion

In our study, both serum CRP levels and IL-6 levels were higher in CKD subjects
compared to controls. CKD is characterized by a chronic state of
inflammation[33], so these results were expected and are consistent with those
reported by others[22-241. The sources of inflammation in CKD patients are still
under investigation, but clotted access grafis[29], atherosclerotic processes[I 091,
and persistent infections[27, 281 have all been suggested to be contributory
factors. Residual renal function may also have an important role in the
inflammatory process. For example, serum IL-6, IL-8, and TNF-alpha levels
have been shown to be elevated in HD patients compared to healthy

controls[25]. In addition, patients on peritoneal dialysis have been reported to
have increased CRP levels during the first year of dialysis[llO]. Animal studies
also suggest a reduced clearance of pro-inflammatory cytokines when renal
function is impaired[l 11, 1121.

Serum CRP levels were significantly higher in HD patients compared to controls.
While pre-dialysis patients had higher CRP levels compared to controls, this
difference did not reach statistical significance. Other studies have found CRP
levels to be elevated in pre-dialysis patients[ll3], and several researchers[ll31151 have found an inverse relationship between GFR and CRP levels in predialysis patients. The exact reason why there was no significant difference in
CRP levels between HD and pre-dialysis patients cannot be explained.
However, the incidence of elevated serum CRP levels has been shown to be
different among different geographical populations~l16],indicating that causes
other than dialysis-related factors such as nutrition and lifestyle can also play a
role in serum CRP levels. Our limited sample size could also explain these
trends as well as our inability to discern a statistically significant difference
between the two CKD populations.

Serum IL-6 levels were significantly higher in HD patients compared to both predialysis patients and healthy controls. Our ,findings of increased IL-6 levels in HD
patients is in agreement with others who have found plasma IL-6 to be elevated
in these patients[ll7, 1181. The lack of a statistically significant difference in IL-6

levels between pre-dialysis patients and controls in some of our analysis is in
contrast to what has been reported by others[l19].

IL-6 levels have been shown to predict mortality in both HD and pre-dialysis
patientsC42, 104, 1181 and may be a better predictor of mortality than CRPCI 191.
This leads one to question whether a medical or pharmacological intervention
can alter this cytokine imbalance to irr~proveoutcomes. Statins and ACEinhibitor drugs administered to CKD patients can lower IL-6 levels in both nonrenal and CKD patients[120-1231, but it is unknown if this affects mortality
outcomes.

As expected, serum IL-6 levels were higher in patients with severe periodontitis
compared to subjects without periodontitis. This is consistent with the findings
reported by others[97, 981. While there were statistically significant differences in
IL-6 levels between periodontitis and non-periodontitis groups, this was not the
case for CRP levels. The finding that CRP levels were higher in non-periodontitis
patients compared to periodontitis patients is unexpected. Other authors[99]
have shown CRP to be elevated in patients suffering from periodontitis, and
treatment of periodontitis has been shown to decrease CRP levels in
systerr~icallyhealthy patients[68], so our findings are inconsistent with previous
reports. This could be accounted for by our limited sample size (n=33) coupled
with the limited number of patients displaying severe periodontitis (n=12). The
mechanism for the differences in serum inflammatory mediators in the presence

of diseased and healthy periodontal tissue is still under investigation. One
possibility is that these mediators are produced from the periodontium itself. It
has been shown that gingival fibroblasts from chronic periodontitis lesions
produce greater amounts of IL-6 than healthy controls[97]. 1L-6 has also been
found to be elevated in the gingival crevicular fluid[124] and serurn[68] of chronic
periodontitis patients. This may be due to polymorphisms resulting in an
increased expression of the IL-6 (-174) gene in the presence of periodontal
infections[l25]. It has been hypothesized that this increase in pro-inflammatory
mediators could theoretically spill over into the circulation, thus inducing systemic
effects11261.

Both serum IL-6 and CRP levels were significantly correlated with plaque scores.
It has been postulated that high-responder individuals produce high levels of
inflammatory mediators and cytokines as part of their host inflammatory
response to the presence of plaque[127, 1281and, consequently, these
individuals are more susceptible to periodontitis. Based on this evidence,
however, we would not expect a direct relationship between inflammatory
mediator level and plaque score. Other authors[74] have found no difference in
gingival index scores between chronic renal failure patients on HD and
systemically healthy control patients with similar levels of plaque, suggesting that

HD patients may exhibit a similar inflammatory response to dental plaque as
healthy patients.

The significance of HD status as an independent predictor of serum IL-6 and
CRP levels in the multivariate analysis was expected, as hemodialysis patients
have been shown to have elevated serum inflammatory markers compared to
non-hemodialysis patientst21-241. In our study, periodontal status was not a
predictor of serum IL-6 or CRP. However, multiple studies performed on nonCKD populations have shown that serum IL-6 and CRP levels are elevated in
periodontal patients when compared to periodontally-healthy controls[65-671, and
that periodontal treatment can reduce levels of these markers[65]. Further
studies on CKD populations are needed to verify our findings. The interaction
between the CKD and periodontal status was not significant for either
inflammatory marker. The limited sample size of our CKD (n=21) and
periodontitis (n=12) subjects in this pilot study could account for these findings.

A limitation of our study was the sample size and the cross-sectional design of
our study does not allow us to make any conclusions regarding a cause and
effect relationship between periodontal disease and systemic inflammation.
Further large-scale, intervention studies are needed.

IV.

Concluding Remarks

I.Severe periodontitis was found to be significantly more prevalent in a

stable CKD population compared to healthy controls. There was no
statistically significant difference in prevalence of severe periodontitis
between hemodialysis, pre-dialysis, and control subjects.

2. Serum IL-6 and CRP levels were statistically significantly higher in CKD

patients compared to healthy controls. For serum IL-6, hemodialysis
patients had significantly higher levels compared to pre-dialysis and
control patients. Serum CRP levels were significantly higher in
hemodialyis and pre-dialysis patients compared to controls. There were
no significant differences in CRP or IL-6 levels between pre-dialysis and
control subjects.

3. Subjects with severe periodontitis had higher serum levels of IL-6
compared to periodontally-healthy subjects. There were no significant
differences with regards to serum CRP levels.

4. HD status was a significant independent predictor of both serum IL-6 and

CRP levels in CKD patients.

V. Index (Tables and Figures)

Table 1: Stages of chronic kidney disease

Stage

Description

Glomen~larFiltration
Rate (GFR)

At increased risk

Risk factors for kidney
disease (e.g. , diabetes,
high blood pressure,
family history, older age,
ethnic group)
Kidney damage (protein
in the urine) and normal
GFR

More than 90

Kidney damage and mild
decrease in GFR

60 to 89

2

3

More .than 90

I Moderate decrease in
GFR

s
Severe decrease in GFR

or kidney transplant
needed)

Table 2: Population characteristics of CKD and control groups

Table 3: Periodontal characteristics of CKD and control groups

Severe
periodontitis

47.6

CAL (mm)

3.2120.18

2.4720.10

0.004

BOP (%)

16.0623.4

15.4723.82

0.45

Missing teeth
(n)

8.0923.23

4.6220.56

0.01

Sites
CAL25mrn

16.8024.22

2.55k1.5

0.001

(%)

Figure 1: Percent of subjects with severe periodontitis

Advanced Periadontitis

Control

CKZI

Figure 2: Comparison of periodontal parameters (PPD, CAL) between CKD and control
groups

Periodontal Parameters

Figure 3: Comparison of periodontal parameters (BOP, PS, CAL25) between CKD and
control groups

Periodontal Parameters

Table 4: Periodontal characteristics of subjects according to renal status

Variable
Severe
periodontitis
(%)
PD (mm)

Hernodialysis Premdialysii Control
Subjects
Subjects
Subjects
(nm.12)
(n=f3)
(nm9)
45.4

P-Value

44.4

15.4

0.13

2.8020.1 la

2.5720.12

2.4+.0.10

0.049

CAL (mm)

3.3220.1ga

3.0620.24~

2.47-cO.10

0.002

BOP (%)

21.74e4.86

9.91k3.59

15.4723.82

0.174

PS (%)

59.4229.88

40.0721 2.30

43.7927.07

0.300

Missing teeth
(n)

6.4221.03

10.6222.65~

4.62k0.56

22.0126.4ga

13.5725.81

2.55k1.5

Sites
CALz5mm
(%)

a - p50.05 between HD and control subjects
b - ps0.05 between pre-dialysis and control subjects
c - p10.05 between HD and pre-dialysis subjects

I
0.030

0.016

Figure 4: Percent of subjects with severe periodontitis according to renal status

Advanced Periodontitis
W

Figure 5: Comparison of periodontal parameters (PPD, CAL) according to renal status

Periodontal Parameters

* p 5 0.05 compared to control group

Figure 6: Comparison of periodontal parameters (BOP, PS, CALr5) according to renal
status

Periodontal Parameters

* p s 0.05 compared to control group

Table 5: Serum inflammatory markers in CKD and control subjects

CRP (pglml)

3.87

0.30-78.35

1.41

0.42-18.00

0.014

IL-6 (pg/ml)

8.72

0.60-9.92

4.00

2.00-5.92

0.038

1

Figure 7 : Comparison of serum CRP levels between CKD and control subjects

Serum CRP Levels

Control

* p s 0.05

Serum IL-6 Levels
*

Ccrritrsl

CKU

Figure 8: Comparison of serum IL-6 levels between CKD and control subjects

Table 6: Serum inflammatory markers in subjects according to renal status

a - p10.05 between HD and control subjects
b - ps0.05 between pre-dialysis and control subjects

c - p50.05 between HD and pre-dialysis subjects

Figure 9: Comparison of serum CRP levels according to renal status

Serum CRP Levels

* p 5 0.05 compared to control group

Figure 10: Comparison of serum IL-6 levels according to renal status

Serum. l L-6 Levels
14

* I
3

I

T

p 5 0.05 compared to control group

** p 10.05 compared to pre-dialysis group

Table 7: Serum inflammatory markers in subjects according to periodontal status

Variable

Non-Periodontitis

Periodontitis

Subjects
(nm22)

Subjects
(n312)

Range

'

P-Value

Median

Range

2.935

0.21-41.8

0.286

6.175

2.00-29.35

0.015

I

CRP (pglml)

3.26

0.42-78.32

IL-6 (pglml)

4.63

2.00-11.35

'

Serum CRP Levels
33

Figure 11: Comparison of serum CRP levels according to periodontal status

Figure 12: Comparison of serum IL-6 levels according to periodontal status

Serum IL-6 Levels

Table 8: Correlations between inflammatory markers and patient characteristics and
periodontal variables

Variable

' Sarum IL-6
I

-I-P
Gender

PS

PD

CAL

CALrBmm

Sarum CRP

Table 9: Multivariable linear regression analysis in CKD patients with serum IL-6 as the
dependent variable

Age (years)

0.938

Glucose (mgldl)

0.662

(yeslno)
Periodontitis
status (yeslno)

status*Periodontal
status

0.350

Table 10: Multivariable linear regression analysis in CKD patients with serum CRP as
the dependent variable

Age (years)

0.165

BMI

0.01 3

1
1
Dialysis status
(yeslno)

0.012

Periodontitis
status (yeslno)

0.432

Dialysis
status*Periodontal

0.256

VI.

Appendix

1) Medical History Questionnaire for Control Subjects

Universiv of Connecticut Health Center
School of Dental Medim~c,UnlversiQ Derltists
MEDICAL HISTORY QZTlf8TIOI8RADLE
( W e n t or Guardian to answer for child under 18 years of agc )
Name

M

Telephone: IHome) .

- .

Today's Date

I
I

-F -Date

_

0rBh-t.b . - . - - _ _ _ _ _ _

..____-

-_.__II_-._-__X

Address

7
-

(Work)

Hekht.

-

Weight

--

Occupation

- --*- .-------.-- -.---.-.APaacr ~ U ; Q Y D ~ + - ~af&@g-BithOl
~J
YE$ or NO. N U in bLnk wpacee arban indicated. ANSWERS
bBE P Q R " O ~ ~ Q R D
O MS Y AND AS& COWmEWT&U.

-7

1. My last medical physic4

cxminarion was on (approx.)

-.---

.

- . .- ----

2. ?'he name & addrcs8 OK my personal physician is

3 Are you now under the care of a physician ................................................................

If yes, what is the condition being treated

YES

NO
.

............

4. Have you had any serious iUness or aperation ...................................................................
YES NO
l i yes, what was the ilincss or operntion
..- ..
-5. Have you b e n hospitalized within the past 5 years ....................................................... YES KO
If yes, what was the problem

-...

...

-

_":..:>--_-

. .<-LIE;E.r-Y-..

6. 110 you have or have you had m y of the lollowing diseases or problems.

Rheumatic Kever or rheumatic heart disease......................................................... YES
abnormalities present since birth.. ............................................................. YfES
Cardiovascular disease (heart wuble, heart attach, angma, stroke, high
blood p~rruure,heart murmur.)................ .
.
.................................................... YES
Do jvu have discomfortor pressure in the chest upon cxertion................................... YES
................................ Yi3S
A r t you mw rhort of b w t h after mild exercise....................
.
.
Do your ankles oweU................................................................................................
YES
Do you get short of hrrath whan you lie down, or do you requim*
..........................................
................
extra pillows
you &cp ..............
....
YES
Have you been DM you have a h e w murmur .......................................................... Y&S

.
.
.

Asthma or hay fever ..............
.........
..............................................................
Hives ur a skin rash ................................................................................................
Fainting spells or scizures...................
.
.
.
.......................................
. . . ...........

YES
YES

YES

Diabetes...................................................................................................................
YES

Jaundice or liver discase........................................................................................
YES
Hepatitis ................................................. ...
........................................................
YES
Arthritis or other Joint problems ............................................................................ YES
.................................................................
Stomach ulcers ...................... .
.
.
YES
Kidney e o q b k ...................................................................................................... YES
Dialysis patient............................. ..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . YES
......................................................................................... YES
Tuberculosis
YES
Do you have a persistent cough or cough up blwd .............................................
Venereal diseuse.....................................................................................................YES
AIDS/ ARC or FIN+...........................
.
.
...................... . . . . . . . . . . . . . . . . . . . . . .
/YES
Other (list)--.-.---.
..... .-.-. .
-. . . . . . . . . .
--

..

............,

....

NO
NO

NO
NO

NO
NO

NO
NO

NU
NO
NO
NO
NO

NO

NO
NO
NO
NO
NO

NO
NO
NO

7. Have you had surgery or radiarion treatment for n tumor, cancer or other condition

.....................................................................

of your head or neck ........................

8 Have you hnd abnormal bleeding assocrated with prenuue extnlslrvrJs, surgery or traurr~a.

YES

NO

YES

NO

1

9 . Do you h ~ v any
e blood disorder such a s anemia, including siclde cell anerriia . . . . . . . . . . . . YES NO
10. Are you a hemophiliac .................,...........,....................................................................
YES NO
11. Are you a present or pact IV drug user .................................................................... YES NO
12. Are you a t increased risk for the H P virus ~r AIDS .......................................................
YES NO
13. Are you taking any drug or medicine ......................................................................... YES NO
14.
Are you taking any of the following:
Antibiotics or sulfa drugs...............................
YES
NO j Drugs for heart troublc lr
\
dipjralis................................ YES
Anucoagukarlts: (blood thinners).......................
YES
KO / Nirroylycrrin ....................... YES
NO ; A~~tihisturnmc
........................ YES
Medicine for high blood pressure...................... YES
Steroids (Prednisone, Cortisone).......................
YES
NO ' 01.al corltrsrceprive or other hor-rllorlal
NO
therapy ................................. YES
Drugs that change your mood. ................... YES
Aspirin .............................
.................. YES NO Anuconvulsarlt dmgs ................ YES
Insulin, tolbutamide (Orinase)or
Sedatives or slecp~ngpilla .......... YES
similar drug................
... ................................ YES NO / Othel. d ~ ~ ---.-g.,- s

..........

NO

NO

NO

1

NO

.

NC

IS. L)o you suffer from any birth defect or other disability ...................................................
YES
16
Are you allergic or have you reacted adversely to:
Local anesthetics...........................................
YES
NO i IodL~eor X.-my dyes . . . . . . . . . . . . .
Penicillin or other antibiotics..........................
YES
NO
Cod~inco r other :rarcoucs. . .
Sulfa drugs.............. ...........................
YES
NO i Other
Aspirin.. .........................................................
YES
KO

No

NO

YES

NO
NO

. . . YOS

NO

YES

NO

......... YES

NO

20. Are you wearing contact lenses....................................................................................YES

NO

Yb;S

.

.
.

17 Have you had nriy serious trouble assoc~atedwith any prevlouv drrltaf treament
If yes, e x p h n

--

18. Do you have any disease, condition, or. problem not Listed above ...........................

If

so,please explain

19. Does your ernpluyment expose you regularly t o x-rtiys or other' i o n l i n g radiation

7-,-

- --- -.

....

------,.-

~ . ^ . : : j . : . ~ i i * . i ~..
. w - - . .

-_.I"X

...

i.+L43

21. Arc you pregnant or have you recently missed a menstrrw.l period................................ YES
22. Are you presently breast feeding................................................................................YES
Chief dental complaint (why did you come to the dentist today?)

TO THE BEST OF

__-

MY KNOWLEDGE, THE ABOVE MFORlldATlON 18 COkWLETE ARD ACCURATE

Signature ol klient or Legal Guardian

*

2) Medical Data Extraction Form for CKD Subjects

NO
NO

Hernodialysis and Predialysis Patient
Chart Review
...

..

.

..

I . Pt ID:
2. 008: .

...

. SECTION 1: PARTICIPANT DEMOGRAPHICS
..... --.......

I

--I

,.

....................

( 3 digit tC)

3. Ethnicity:

1

1- Asian [ ] 2-Black [ ] 3-White [

5-Am IndiAlaska Native [ ]
Gender:

4

..

.

..

-

male 1 ]

4-Native Hawaiian!Pacific Islander [ ]

6-H~spanic[ J

female [ ]

-

--

SECT^^

-...

..

.-

5. Does the patient have history of diabetes?
If yes. Type I [ ]

7-Unknown [ ]

Type li

[I

6. Is the patlent a smoker? Current

Y []

N[

1

Insultn-requiricg [ ]

[I

Former [ ]

Never srncked 1, ]

lOlnfect~onwRhm the last 2 months (vascular access/f~stula UTI, b r o n c h ~ ! ! ~ ,
peritonitis. prieurnorla, abdom~rlalabscess elc)
- .-

CB td
1

tees
-

;,i:12:;r

ra<,e 3 ::,stc:%j
~f cadi3vjsci. a:

- 5 1':'2<s 3Ppf;p:!Jid

,:I;~,;I:CS.S

3i5~3~E:)

.< : !

N

j

7

12. Does the patient have history of hypertension'?

y[l

NI1

:3. What is the patient's yre-dialysis k~dneydisease diagnosis?

(Please specify

etiology of underlying disease)

-....
--

-

-.-.....................

. . . . . . . . . . .

SECTION 3: Biochemical
data (Most recent)
............................................................

......

...-.

...

14 Serum alburn~n

15 Blood urea nltrogen

(BUN)

.

-

16. Creatinine:..

17.Ferritin level.

-.

,_".--a-

18.Total Iron B~ndingCapacity (TIBC)
19.Total cholesterol:
20. HDL-cholesterol:

-.

2 2 . Trigycerides:

(only for he~rlodialyslss~lbjects)

23. Dialysis adequacy (KW):
24. Dialysis vintage (years on d~alys~s)

(only for heniod~alys~s
subjects)

.............

: MEDI
.25 Has the pattent been on non-stero~dalanu-~nflammatoryrnedlcatlon ~ ~ t hthe
in

last month?
"I1 N[1
Dose

--

Duratloq

---

26 Has tlle patterit eve! tael-I en a~ltt-tiypetlipiddin~i
'~lads?

Dose:

Duration'

Y []

N [

1

.

/

27 Please attach medication list:
..
.......................

.,...............................

28. Please attach SF-36 questionnaire

3) Abbreviations used
ANOVA - Analysis of variance
AV - Arteriovenous
BGI - Biofilm-gingival interface
BMI - Body mass index
BOP - Bleeding on probing

BUN - Blood urea nitrogen
CAL - Clinical attachment loss
CKD - Chronic kidney disease
CRP - C reactive protein

CVD - Cardiovascular disease
ELlSA - Enzyme-linked irr~munosorbentassay
ESRD - End stage renal disease
GFR - Glornerular filtration rate
HD - Hemodialysis
HDL - High density lipoprotein
Ig - lmmunoglobulin
IL - Interleukin
IRB - Institutional Review Board

LDL - Low density lipoprotein
PPD - Pocket probing depth

TlBC - Total iron binding capacity
UCHC - University of Connecticut Health Center
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